Changchun High-Tech Industry(000661.SZ): The application for registration clinical trials of GenSci161 injection liquid, a domestically produced drug, has been accepted.

Changchun High-Tech Industry (000661.SZ) announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), has received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci161 injection. GenSci161 injection can target two subtypes of key proinflammatory cytokine interleukin-1 (IL-1) - IL-1 and IL-1 at the same time, which is expected to inhibit the activation of downstream inflammatory signaling pathways, providing a new long-term systemic treatment option for patients with moderate to severe conditions. Currently, GenSci161 injection has shown good efficacy in preclinical animal models, demonstrating its potential in treating endometriosis and pyogenic hidradenitis.